or Try an Advanced Search...

    ETF Components for EDEN - iShares MSCI Denmark Capped ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    NVO F -0.01 22.75
    TRMD F -0.96 0.97

    Represented by ETF Holdings

    Keywords: Anti Diabetic Drugs Biopharmaceutical Bulk Carrier Chemical Substances Diabetes Diabetes Care Endocrine System Gas Oil Glucagon Like Peptide 1 Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones Inflammation Insulin Life Sciences Liquid Fuels Obesity Oil Refinery
    Industries: Biotechnology Shipping & Ports

    Recent News for iShares MSCI Denmark Capped ETF & its Holdings

    Date Stock Title
    Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
    Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
    Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
    Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
    Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
    Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
    Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
    Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
    Oct 31 NVO Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
    Oct 30 NVO Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
    Oct 30 NVO Eli Lilly plans to begin advertising weight-loss drug Zepbound
    Oct 30 NVO Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
    Oct 30 NVO Novo takes big step toward ending Ozempic, Wegovy shortages
    Oct 30 NVO Eli Lilly drops, sending Novo lower after Q3 miss
    Oct 30 NVO Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations
    Oct 30 NVO Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
    Oct 30 NVO The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
    Oct 30 NVO Lilly shares fall as obesity drug sales miss forecasts
    Oct 29 NVO Key Novo Nordisk plant where Wegovy, Ozempic made cited by FDA
    The investment seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the MSCI Denmark IMI 25/50 Index (the "underlying index"). The fund will at all times invest at least 90% of its assets in the securities of the underlying index or in depositary receipts representing securities in its underlying index. The underlying index is designed to measure broad-based equity market performance in Denmark. A capping methodology is applied that limits the weight of any single component to a maximum of 25% of the underlying index. The fund is non-diversified.
    Exchange Traded Fund ETF Exchange Traded Funds Bond Market MSCI EAFE
    Back to the Main EDEN Page...